Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Change in Intangibles (2019 - 2022)

Historic Change in Intangibles for Sanara MedTech (SMTI) over the last 4 years, with Q3 2022 value amounting to -$1.5 million.

  • Sanara MedTech's Change in Intangibles fell 35125.43% to -$1.5 million in Q3 2022 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year change of. This contributed to the annual value of $23452.0 for FY2024, which is N/A changed from last year.
  • Sanara MedTech's Change in Intangibles amounted to -$1.5 million in Q3 2022, which was down 35125.43% from $578586.0 recorded in Q3 2021.
  • Sanara MedTech's 5-year Change in Intangibles high stood at $1.0 million for Q3 2019, and its period low was -$1.5 million during Q3 2022.
  • For the 4-year period, Sanara MedTech's Change in Intangibles averaged around $291224.8, with its median value being $539293.0 (2019).
  • Within the past 5 years, the most significant YoY rise in Sanara MedTech's Change in Intangibles was 35125.43% (2022), while the steepest drop was 35125.43% (2022).
  • Over the past 4 years, Sanara MedTech's Change in Intangibles (Quarter) stood at $500000.0 in 2019, then grew by 20.0% to $600000.0 in 2020, then fell by 3.57% to $578586.0 in 2021, then plummeted by 351.25% to -$1.5 million in 2022.
  • Its last three reported values are -$1.5 million in Q3 2022, $578586.0 for Q3 2021, and $600000.0 during Q2 2020.